Page 2 - Database Consortium News Today

Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs. sunitinib at eight years from the...

Expert oncologists who treat patients with advanced RCC discuss updates from clinical trials presented during the 2023 European Society for Medical Oncology Congress that further defined the treatment paradigm in advanced RCC and gave a peek into the potential future of the disease management.

First and only hypoxia-inducible factor-2 alpha inhibitor approved for these adult patients with advanced RCC This approval of WELIREG marks the first time a new treatment has been approved in a...

The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in...

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.